2020
Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives
Aapro M, Bossi P, Dasari A, Fallowfield L, Gascón P, Geller M, Jordan K, Kim J, Martin K, Porzig S. Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives. Supportive Care In Cancer 2020, 28: 4589-4612. PMID: 32533435, PMCID: PMC7447627, DOI: 10.1007/s00520-020-05539-1.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesSupportive careDigital health solutionsHealth solutionsHealth economic endpointsOncology supportive careRoutine supportive careHealthcare resource utilizationOptimal supportive careImprovement of QoLTreatment of symptomsPatient-centered careEvidence-based therapeutic interventionsDifferent healthcare systemsUnplanned hospitalizationMost patientsSymptom supportOncology practiceSymptom distressClinical studiesPatient managementOral drugsSymptom monitoringPatient complianceTreatment efficacy
2014
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046).
Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kelly K, Agarwal PK, Koppie TM, Kaag MG, Quinn DI, Vogelzang NJ, Sridhar SS. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046). Urologic Oncology Seminars And Original Investigations 2014, 32: 637-644. PMID: 24840869, PMCID: PMC6771274, DOI: 10.1016/j.urolonc.2013.12.012.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerTreatment of MIBCUpper tract urothelial carcinomaNeoadjuvant chemotherapyMedical oncologistsUrothelial carcinomaBladder cancerEastern Cooperative Oncology Group performance statusHigh grade upper tract urothelial carcinomaBladder Cancer Advocacy NetworkUse of NACDose-dense methotrexateGemcitabine/carboplatinGemcitabine/cisplatinGlomerular filtration rateAdjuvant chemotherapyPerioperative chemotherapyChemotherapy regimensLymphovascular invasionPerformance statusT2 lesionsStandardization of practiceMost referralsFiltration rateChemotherapy management